Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
GlobalData on MSN23h
DMTs are major clinical research focus for Parkinson’s disease, analysis showsAnalysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
News Medical on MSN16h
New biomarker could help predict Parkinson’s disease progressionA team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.
Molson Coors Beverage Co. Cl B $61.89 1.39 2.30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback